Everything about bladder cancer in detail with reference to standard textbooks

Reading File

Finding Sources

Searching PubMed

"bladder cancer" AND "urothelial carcinoma"

Reading File

Loading Image

I now have extensive, authoritative content from multiple standard textbooks plus excellent visual diagrams. Let me compile the comprehensive answer.

Bladder Cancer - A Comprehensive Review

Sources: Campbell-Walsh-Wein Urology (11e), Goldman-Cecil Medicine, Bailey & Love's Short Practice of Surgery (28e), Gray's Anatomy for Students

1. Definition and Overview

Bladder cancer encompasses a spectrum of tumors arising from the urothelial lining of the bladder, renal pelvis, ureters, and urethra. Over 90% originate in the bladder itself. Transitional cell (urothelial) carcinoma is the most common histologic type. These tumors have a particular tendency for multifocality, high recurrence rates, and potential for progression to higher stages.

They are broadly classified into three categories that differ in clinical behavior, prognosis, and management:

Non-muscle-invasive bladder cancer (NMIBC) - stages Tis, Ta, T1
Muscle-invasive bladder cancer (MIBC) - stages T2-T4
Metastatic disease

Long-term cure ranges from 99% for low-grade Ta tumors to approximately 15% for metastatic disease. - Goldman-Cecil Medicine

2. Epidemiology

Parameter	Data
New US cases/year	~80,000
US deaths/year	~17,000
5-year overall survival	77%
Male:Female ratio	3:1
Rank in men	4th most common cancer
Lifetime risk (men)	1 in 27
Lifetime risk (women)	1 in 89
White:Black prevalence	2:1
Median age at diagnosis	73 years
Global cases (2015)	~540,000
Global deaths (2015)	~188,000

Goldman-Cecil Medicine; Bailey & Love's Short Practice of Surgery (28e)

3. Etiology and Risk Factors

Carcinogens and their metabolites excreted in urine act directly on the urothelial lining. The latency period from initial exposure to cancer development is nearly 20 years.

3.1 Cigarette Smoking

The leading risk factor, contributing to 50% of cancers in men and 25% in women
Smokers have a 2-4 fold higher relative risk than non-smokers
Duration of exposure matters more than intensity (cigarettes/day)
Urothelial cellular atypia found in only 4% of non-smokers vs. 50% of smokers
Goldman-Cecil Medicine

3.2 Occupational Exposure

Polycyclic aromatic hydrocarbons: 2-naphthylamine, 4-aminobiphenyl, benzidine, benzene
Arylamines: metabolically activated to electrophilic compounds by N-hydroxylation via cytochrome P-450 IA2; detoxified by N-acetylation
Individuals with fast oxidizer + slow acetylator phenotype are at highest risk
High-risk occupations:
- Dye, rubber, leather manufacturing workers
- Aluminum workers, dry cleaners
- Pesticide applicators, painters, hairdressers, plumbers, tanners

3.3 Chronic Inflammation

Schistosoma haematobium infection - enhances N-nitroso compound formation; associated primarily with squamous cell carcinoma in endemic areas
Indwelling catheters, bladder stones, recurrent UTIs - associated with squamous cell carcinoma
Goldman-Cecil Medicine; Bailey & Love (28e)

3.4 Drugs

Cyclophosphamide - increases risk 9-fold with chronic use (via acrolein metabolite)
Phenacetin - associated with renal pelvis and ureteral tumors

3.5 Other Factors

Pelvic radiotherapy - increased risk
Arsenic in drinking water
Genetic susceptibility - GWAS have identified 11+ replicated susceptibility loci including: 1p13.3 (GSTM1), 3q28 (TP63), 4p16.3 (FGFR3), 5p15.33 (hTERT), 8p22 (NAT2), 8q24.21 (MYC), 8q24.3 (PSCA), 19q12 (CCNE1)
About 15% of patients have germline variants in DNA-damage repair genes (BRCA2, BRCA1, MSH2, CHEK2, ERCC3, NBN, RAD50)
Campbell-Walsh-Wein Urology; Goldman-Cecil Medicine

4. Pathology and Histological Types

Histologic Type	Frequency
Transitional cell (urothelial) carcinoma	>90%
Squamous cell carcinoma	1-7%
Adenocarcinoma	2%
Small cell carcinoma	~1%
Melanoma, lymphoma, sarcoma, pheochromocytoma	<1%
Metastatic (colorectal, prostate, kidney, ovary)	<1%

Bailey & Love (28e); Goldman-Cecil Medicine

4.1 Urothelial (Transitional Cell) Carcinoma

The vast majority. Can show divergent differentiation into squamous, glandular, or neuroendocrine elements.

4.2 Squamous Cell Carcinoma

Occurs secondary to chronic inflammation (indwelling catheter, stones, schistosomiasis, chronic UTI leading to keratinizing squamous metaplasia).

4.3 Adenocarcinoma

Usually originates in the urachus (dome of the bladder) or in those with bowel in the urinary tract (augmentation enterocystoplasty, bladder exstrophy repair).

4.4 Histologic Variants of Urothelial Carcinoma

These variants generally signify aggressive tumours with poorer prognosis than pure urothelial carcinoma:

Micropapillary variant (0.7-2.2% of urothelial tumors)

Strong male predominance (male:female ratio up to 37:1)
50% are stage T3 or T4 at diagnosis
5-year and 10-year OS: 51% and 24%
Progression from NMIBC to MIBC: 70%
Histologically: small tight clusters or thin papillae with prominent retraction artifact
BCG therapy is ineffective; early cystectomy is recommended
Characterized by ERBB2 amplification; evolves through luminal pathway

Other variants: Sarcomatoid, plasmacytoid, nested variant, glandular, squamous

Campbell-Walsh-Wein Urology; Bailey & Love (28e)

5. Molecular Pathobiology

Bladder cancer has a very high somatic mutation rate (7.7 per megabase), exceeded only by lung cancer and melanoma. - Goldman-Cecil Medicine

5.1 Key Molecular Alterations

EGFR: highly expressed in ~80% of bladder cancers
HER2/Neu: expressed in ~50-70%; higher expression = more aggressive phenotype
TP53: mutated in 49% of tumors
RB1: mutated in 13% of tumors
Epigenetic modifying genes (MLL2, ARID1A, KDM6A, EP300): ~75% have at least one inactivating mutation
FGFR, ERBB2, MDM2, EGFR amplifications: minority of tumors; represent therapeutic targets

5.2 Molecular Subtypes (from genome-wide expression studies)

Luminal phenotype: high levels of FGFR3, GATA3, KRT20, PPARG mutations
Basal phenotype: squamous differentiation, expression of CK5, CK6, CK14, low FOXA1 and GATA3

5.3 GWAS Pathway Analysis

Susceptibility variants belong to three fundamental cellular processes: metabolic detoxification, mitosis, and chromatin-mediated vesicles. - Campbell-Walsh-Wein Urology

6. Staging

Approximately 70% of tumours are NMIBC at presentation; 30% are MIBC or metastatic. - Bailey & Love (28e)

Figure: TNM Staging of Primary Tumour in Bladder Cancer. (Bailey & Love, 28e / Reproduced from Magers et al. Histopathology 2019)

TNM T-Stage Classification

Stage	Description
Tis	Carcinoma in situ (flat, high-grade, non-invasive)
Ta	Non-invasive papillary urothelial carcinoma (confined to urothelium)
T1	Invasion into lamina propria (submucosa)
T2a	Invasion into inner half of muscularis propria
T2b	Invasion into outer half of muscularis propria
T3a	Microscopic invasion into perivesical soft tissue
T3b	Macroscopic invasion into perivesical soft tissue
T4	Invasion into adjacent organs (prostate, uterus, vagina, pelvic/abdominal wall)

Note: In diverticula, muscularis propria is absent, so there is no T2 stage.

Grading

G1: Well differentiated
G2: Moderately differentiated
G3: Poorly differentiated

Bailey & Love (28e)

7. Clinical Manifestations

Painless haematuria - the cardinal symptom, present in 80-90% of bladder cancers
Storage LUTS - frequency, urgency, dysuria, nocturia (irritative symptoms or reduced bladder capacity)
Recurrent UTI
Flank pain - if ureteral orifice obstruction with hydronephrosis
Lower abdominal pain - from bladder mass
Pelvic/perineal pain - tumors invading the prostate or pelvis
Weight loss, anorexia, fatigue - advanced/metastatic disease
Bone pain, lower limb oedema - metastatic spread

Physical examination is frequently unremarkable in early disease as most patients have organ-confined tumors. - Goldman-Cecil Medicine; Bailey & Love (28e)

8. Diagnosis and Investigation

8.1 Urine Studies

Urine culture - to exclude infection
Urinary cytology - identifies malignant cells; high specificity for high-grade tumors
Urinary biomarkers - panels of epigenetic markers under study; none has surpassed accuracy of cystoscopy for routine use

8.2 Imaging

CT urography (CTU) - gold standard for upper tract evaluation; detects hydronephrosis and nodal metastases
MRI bladder - useful for staging the primary tumour, particularly for assessing depth of invasion
CT chest - complete staging once bladder cancer confirmed
Important: Imaging should be done before TURBT as post-TURBT oedema can simulate T3 disease on imaging (false-positive overstaging)

8.3 Cystourethroscopy (Key Investigation)

Flexible cystourethroscopy under local anaesthetic is the mainstay of diagnosis
Should always be performed in patients with haematuria
Inspection details: size, number, location, growth pattern (papillary vs. solid) of all lesions
Blue-light (photodynamic) cystoscopy: hexaminolevulinate (HAL) instilled intravesically; cancer cells accumulate porphyrins and fluoresce pink/red - improves detection of flat lesions (CIS)
Narrow-band imaging (NBI): enhances vascular contrast - aids detection of flat lesions

8.4 Transurethral Resection of Bladder Tumour (TURBT) - Diagnostic and Therapeutic

All visible disease undergoes TURBT to determine histologic subtype and depth of invasion
Muscle must be identified in the pathologic specimen - critical for staging
Biopsies from areas of erythema to assess for CIS
Urethra inspected during withdrawal; biopsies taken if clinically indicated
Patients with positive cytology but no visible tumor in bladder should undergo upper tract evaluation and urethral biopsies

Goldman-Cecil Medicine; Bailey & Love (28e)

9. Management of Non-Muscle-Invasive Bladder Cancer (NMIBC)

Stages: Tis, Ta, T1. Affects ~70% at presentation. Aim: prevent recurrences and progression.

9.1 Risk Stratification (EAU Guidelines)

Risk Group	Characteristics
Low	Single, low-grade Ta, <3 cm, no CIS
Intermediate	Multifocal/recurrent low-grade Ta
High	T1 high-grade, CIS, multifocal/large high-grade Ta

9.2 Initial TURBT

All NMIBC is managed with TURBT as the primary treatment.

9.3 Intravesical Mitomycin C (MMC)

For low- and intermediate-risk tumors
Single immediate post-operative instillation of MMC recommended within hours of TURBT to destroy circulating tumor cells and implantation
A 6-week course for intermediate-risk tumors reduces recurrence risk
Bailey & Love (28e)

9.4 Repeat TURBT

Mandatory for high-grade or T1 tumors, performed 2-6 weeks after initial TURBT
Purpose: identify residual tumor, confirm staging
Upstaging to MIBC found in up to 40% of cases - Bailey & Love (28e)

9.5 Intravesical BCG (Bacillus Calmette-Guérin)

For high-risk tumors (T1 HG, CIS, multifocal HG Ta)
Reduces risk of progression to MIBC
Protocol: 6 weekly instillations (induction), then 3-weekly maintenance every 6 months for 3 years
Side effects: transient fever, dysuria, BCG sepsis (rare), BCG cystitis (may necessitate cystectomy)
Bailey & Love (28e)

10. Management of Muscle-Invasive Bladder Cancer (MIBC)

Stages T2-T4. Two primary radical treatment options: radical cystectomy or chemoradiotherapy. 5-year survival with either modality: approximately 60%.

10.1 Neoadjuvant Chemotherapy

Cisplatin-based chemotherapy given before radical cystectomy
Improves survival by 5-7% - Bailey & Love (28e)
Standard regimen: GC (gemcitabine + cisplatin) or MVAC (methotrexate, vinblastine, doxorubicin, cisplatin)

10.2 Radical Cystectomy

The primary surgical radical treatment. Preferred for patients with:

Poor bladder function
Significant haematuria
Upper tract obstruction
Widespread CIS
Factors precluding radiotherapy (bilateral hip replacements, inflammatory bowel disease)

Procedure:

Removal of bladder + pelvic lymphadenectomy (standard)
In males: removal of prostate, seminal vesicles
In females: uterus, ovaries, anterior vaginal wall sometimes included

Perioperative morbidity: up to 50% - major surgery requiring thorough anaesthetic assessment.

Sexual function: Male patients should be counselled about erectile dysfunction and anejaculation; nerve-sparing dissection is possible in some.

10.3 Urinary Diversion

After cystectomy, alternative drainage is essential:

Figure: Techniques of urinary diversion. (a) Ileal conduit - ureters spatulated and anastomosed to ileum; (b) Ureterosigmoidostomy; (c) Ileal neobladder with antireflux long afferent limb. (Bailey & Love 28e)

Type	Description	Notes
Ileal conduit	Ureters joined to a loop of ileum brought out as urostomy	Standard; simplest
Orthotopic neobladder	Ileal reservoir anastomosed to urethra	Voiding per urethra; nerve preservation needed
Heterotopic continent pouch	Ileal reservoir with continent abdominal stoma (e.g. appendicovesicostomy)	Patient self-catheterizes
Ureterosigmoidostomy	Ureters implanted into sigmoid colon	Historical; risk of metabolic complications

Complications of continent pouches:

Ureteroileal leak or stricture
Urinary leak from pouch
Stone formation, UTIs
Metabolic complications: hyperchloraemic metabolic acidosis
Adenocarcinoma (5%, rare)
Stenosis and incontinence (appendicovesicostomy); up to 50% require revision surgery over 5 years

Bailey & Love (28e)

10.4 Radical Radiotherapy

Option for very elderly or unfit patients unsuitable for radical cystectomy
Dose: 66 Gy in 30 fractions over 6 weeks
Long-term urinary and bowel side effects can impair quality of life
Risk of secondary malignancy and fistula

10.5 Bladder-Preservation Trimodality Therapy

Radical TURBT + neoadjuvant chemotherapy + chemoradiotherapy
Being studied for very localised MIBC
Remains an option only for a very select group - Bailey & Love (28e)

11. Management of Metastatic Bladder Cancer

11.1 First-line Chemotherapy

GC (gemcitabine + cisplatin) - equivalent efficacy to MVAC with less toxicity; current standard
MVAC (methotrexate, vinblastine, adriamycin, cisplatin) - older regimen; high-dose MVAC with growth factors also used
A subset of patients may achieve long-term cure

11.2 Immunotherapy (Checkpoint Inhibitors)

Antibodies targeting the PD-L1/PD-1 pathway showing promising results in neoadjuvant, adjuvant, and metastatic settings
Approved agents include pembrolizumab (anti-PD-1), atezolizumab (anti-PD-L1), avelumab, nivolumab, durvalumab
Bailey & Love (28e); Goldman-Cecil Medicine

11.3 Targeted Therapies

FGFR inhibitors (e.g., erdafitinib) for FGFR2/FGFR3 mutations
ERBB2 (HER2)-targeted therapies
Antibody-drug conjugates (ADCs): enfortumab vedotin (anti-Nectin-4), sacituzumab govitecan - represent major advances in the field

11.4 Upper Tract Urothelial Carcinoma (UTUC)

Low-grade: endoscopic treatment
High-grade: nephroureterectomy (ureter also removed due to risk of multifocal disease)
Adjuvant systemic chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine) for high-risk pathologic features
Goldman-Cecil Medicine

12. Prognosis

Stage/Grade	5-year Survival
Low-grade Ta	~99%
T1 (NMIBC)	Variable; high risk of recurrence (~70%) and progression
T2 (MIBC)	~60% with radical treatment
T3	~30-40%
T4/Metastatic	~15%

Recurrences after therapy are frequent in NMIBC (75-85% of presentations are of superficial type), requiring diligent and lifelong surveillance cystoscopy. - Campbell-Walsh-Wein Urology

13. Surveillance

Cystoscopy every 3 months for the first 2 years, then 6-monthly, then annually for NMIBC
Upper tract imaging periodically
Urinary cytology at each visit

14. Recent Evidence (2024-2026)

Recent systematic reviews highlight evolving approaches:

Novel intravesical therapies for NMIBC are expanding beyond BCG, including TAR-200 (intravesical gemcitabine-releasing device), cretostimogene, nadofaragene firadenovec - [Ghodoussipour et al., Eur Urol 2025, PMID 40253283]
Mitomycin C in intermediate-risk NMIBC: A 2024 meta-analysis confirms a role for extended MMC instillation in reducing recurrence - [Scilipoti et al., Eur Urol Oncol 2024, PMID 38902138]
Nectin-4 (target of enfortumab vedotin) is consistently expressed in urothelial and other genitourinary malignancies - [Crupi et al., JCO Precis Oncol 2024, PMID 39626158]

Summary Table: Key Points

Feature	Details
Most common type	Urothelial (transitional cell) carcinoma >90%
Cardinal symptom	Painless haematuria (80-90%)
Leading risk factor	Cigarette smoking (2-4x risk)
Occupational risk	Aromatic amines (dye, rubber, leather workers)
Diagnosis gold standard	Cystoscopy + TURBT
Staging tool	CT urography
NMIBC treatment	TURBT ± intravesical MMC or BCG
MIBC treatment	Neoadjuvant chemo + radical cystectomy
Metastatic treatment	GC chemotherapy, checkpoint inhibitors, ADCs
Mutation rate	7.7/Mb (3rd highest of all cancers)
Recurrence rate NMIBC	High; lifelong surveillance required

References:

Goldman-Cecil Medicine (International Edition, 2-Volume Set), Chapter 100
Campbell-Walsh-Wein Urology (3-Volume Set), Chapters 33, 75, 84
Bailey & Love's Short Practice of Surgery (28th Edition), Chapter 83
Gray's Anatomy for Students
Scilipoti et al. [Eur Urol Oncol 2024, PMID 38902138]
Ghodoussipour et al. [Eur Urol 2025, PMID 40253283]
Crupi et al. [JCO Precis Oncol 2024, PMID 39626158]

This is a shared conversation. Sign in to Orris to start your own chat.